Canaccord Genuity Rates Tango Therapeutics (TNGX) buy

Canaccord Genuity maintains its buy rating and $46 price target on Tango Therapeutics, Inc., keeping an upbeat view on its precision oncology pipeline, a 47.15% upside from the current price.

By EarningsIQ Research Desk · Published Jun 29, 2026, 10:00 AM EDT · Updated Jul 1, 2026, 10:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Canaccord Genuity rated Tango Therapeutics, Inc. ($TNGX) "buy" with a $46 price target on June 29, 2026.

Since the rating, $TNGX is down 8.1% after 1 week, down 20.6% after 1 month and down 32.3% to date (from the $32.56 close on Jun 29, 2026).

TNGX Tango Therapeutics, Inc.

$22.04 +146.81% year to date

Daily close · Oct 16, 2026

Key Points

Canaccord Genuity analyst John Newman reiterated a buy rating on Tango Therapeutics, Inc. (NasdaqGM: TNGX) with a $46 price target on June 29, 2026.
Canaccord Genuity's $46 price target implies 47.15% upside from Tango Therapeutics, Inc.'s ($TNGX) current $31.26 share price.
The stock traded around $31.26 on Monday, riding strong momentum after recent updates from other Wall Street research desks.
Tango Therapeutics carries a strong buy consensus across eleven analyst opinions, with an average target price of $45.18.

Get $TNGX trade alerts by text

We text you when insiders, Congress or big funds trade $TNGX. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Tango Therapeutics, Inc. alert may contain errors. Disclosures

Canaccord Genuity Keeps Buy View on Tango Therapeutics

Canaccord Genuity kept its bullish stance on Tango Therapeutics, Inc. (NasdaqGM: TNGX) on June 29, 2026. Analyst John Newman reaffirmed a buy rating on the biotechnology firm alongside a $46 price target. The update highlights confidence in the company's precision oncology programs targeting hard-to-treat cancers.

Analyst rating track record

Canaccord Genuity vs. the S&P 500

YTD return -38.59% hypothetical

All-time return -0.29% S&P 500 +36.61%

vs. S&P 500 -36.90% behind the index

Hypothetical returns from Canaccord Genuity's disclosed trades, not real profit or advice. How we model this.

TNGX Stock Moves Near Recent Highs

Tango Therapeutics shares recently changed hands at $31.26. The stock has experienced substantial upward movement over the past year, trading well above its 50-day moving average of $25.64 and its 200-day moving average of $20.27. The current share price sits close to its 52-week peak of $34.39, marking a sharp recovery from its 52-week low of $6.69.

12-month forecast

$TNGX price target

Tango Therapeutics, Inc. daily closes and this analyst's $46 target. Not advice.

Wall Street Update and Analyst Coverage

Other research firms have adjusted their views on Tango Therapeutics through the summer and fall. Jefferies kicked off the summer wave on June 26, 2026, by upgrading the stock to a buy and lifting its target to $60 from $27. Following Canaccord's June note, Mizuho maintained an outperform rating on July 17, 2026, with a target of $40. JP Morgan initiated coverage on July 15, 2026, with an overweight rating and a $46 price target. Guggenheim kept a buy rating on August 12, 2026, while bumping its target to $35 from $32. HC Wainwright & Co. maintained a buy rating on August 18, 2026, while raising its target to $68 from $66. Finally, William Blair initiated coverage with an outperform rating on October 16, 2026. The broader analyst community maintains a strong buy consensus, with eleven tracking firms setting targets ranging from a low of $24 to a high of $69, averaging out to $45.18.

Inside the Pipeline at Tango Therapeutics

Tango Therapeutics, Inc. is a Boston-based precision oncology company founded in 2017 that develops targeted therapies for defined patient populations with high unmet medical needs. The company works on PRMT5 inhibitors, including TNG462 for pancreatic and lung cancer, and TNG456 for glioblastoma. It is also advancing TNG260 to counter immune evasion effects in lung cancer. Because the firm focuses on early-stage clinical trials, it is not yet profitable, meaning it has no meaningful P/E ratio.

What to Watch at Tango Therapeutics, Inc.

Investors will look toward the company's next financial update on November 4, 2026, for further updates on clinical trial progress and cash runway. The company maintains strong liquidity with a current ratio of 50.82, ensuring ample backing for its ongoing research programs.